288 related articles for article (PubMed ID: 8709214)
21. Zidovudine and lamivudine: results of phase III studies.
Staszewski S
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
[TBL] [Abstract][Full Text] [Related]
22. Infectious amplification of wild-type human immunodeficiency virus from patients' lymphocytes and modulation by reverse transcriptase inhibitors in vitro.
Mathez D; Schinazi RF; Liotta DC; Leibowitch J
Antimicrob Agents Chemother; 1993 Oct; 37(10):2206-11. PubMed ID: 7504908
[TBL] [Abstract][Full Text] [Related]
23. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.
Gu Z; Gao Q; Fang H; Salomon H; Parniak MA; Goldberg E; Cameron J; Wainberg MA
Antimicrob Agents Chemother; 1994 Feb; 38(2):275-81. PubMed ID: 7514855
[TBL] [Abstract][Full Text] [Related]
24. In vitro selection of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine.
Dianzani F; Antonelli G; Turriziani O; Dong G; Capobianchi MR; Riva E
Antiviral Res; 1992 May; 18(1):39-52. PubMed ID: 1384427
[TBL] [Abstract][Full Text] [Related]
25. Reverse transcriptase sequence of paired isolates of cerebrospinal fluid and blood from patients infected with human immunodeficiency virus type 1 during zidovudine treatment.
Di Stefano M; Sabri F; Leitner T; Svennerholm B; Hagberg L; Norkrans G; Chiodi F
J Clin Microbiol; 1995 Feb; 33(2):352-5. PubMed ID: 7536214
[TBL] [Abstract][Full Text] [Related]
26. Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients.
Mohri H; Singh MK; Ching WT; Ho DD
Proc Natl Acad Sci U S A; 1993 Jan; 90(1):25-9. PubMed ID: 7678340
[TBL] [Abstract][Full Text] [Related]
27. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.
Back NK; Nijhuis M; Keulen W; Boucher CA; Oude Essink BO; van Kuilenburg AB; van Gennip AH; Berkhout B
EMBO J; 1996 Aug; 15(15):4040-9. PubMed ID: 8670908
[TBL] [Abstract][Full Text] [Related]
28. Analysis of the Zidovudine Resistance Mutations T215Y, M41L, and L210W in HIV-1 Reverse Transcriptase.
Boyer PL; Das K; Arnold E; Hughes SH
Antimicrob Agents Chemother; 2015 Dec; 59(12):7184-96. PubMed ID: 26324274
[TBL] [Abstract][Full Text] [Related]
29. The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations.
Miranda LR; Götte M; Liang F; Kuritzkes DR
Antimicrob Agents Chemother; 2005 Jul; 49(7):2648-56. PubMed ID: 15980332
[TBL] [Abstract][Full Text] [Related]
30. AZT-related mutation Lys70Arg in reverse transcriptase of human immunodeficiency virus type 1 confers decrease in susceptibility to ddATP in in vitro RT inhibition assay.
Sharma PL; Chatis PA; Dogon AL; Mayers DL; McCutchan FE; Page C; Crumpacker CS
Virology; 1996 Sep; 223(2):365-9. PubMed ID: 8806572
[TBL] [Abstract][Full Text] [Related]
31. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication.
Naeger LK; Margot NA; Miller MD
Antivir Ther; 2001 Jun; 6(2):115-26. PubMed ID: 11491416
[TBL] [Abstract][Full Text] [Related]
32. Prevalence of primary resistance to zidovudine and lamivudine in drug-naive human immunodeficiency virus type-1 infected patients: high proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus.
Trabaud MA; Leriche-Guerin K; Regis C; Bordes I; Cotte L; Detmer J; Kolberg J; Ritter J; Trépo C
J Med Virol; 2000 Jul; 61(3):352-9. PubMed ID: 10861645
[TBL] [Abstract][Full Text] [Related]
33. AZT resistance alters enzymatic properties and creates an ATP-binding site in SFVmac reverse transcriptase.
Schneider A; Schweimer K; Rösch P; Wöhrl BM
Retrovirology; 2015 Feb; 12():21. PubMed ID: 25808094
[TBL] [Abstract][Full Text] [Related]
34. Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect.
Jeeninga RE; Keulen W; Boucher C; Sanders RW; Berkhout B
Virology; 2001 May; 283(2):294-305. PubMed ID: 11336554
[TBL] [Abstract][Full Text] [Related]
35. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy.
Richman DD; Havlir D; Corbeil J; Looney D; Ignacio C; Spector SA; Sullivan J; Cheeseman S; Barringer K; Pauletti D
J Virol; 1994 Mar; 68(3):1660-6. PubMed ID: 7509000
[TBL] [Abstract][Full Text] [Related]
36. Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1.
García-Lerma JG; Gerrish PJ; Wright AC; Qari SH; Heneine W
J Virol; 2000 Oct; 74(20):9339-46. PubMed ID: 11000201
[TBL] [Abstract][Full Text] [Related]
37. Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro.
Johnson VA; Merrill DP; Videler JA; Chou TC; Byington RE; Eron JJ; D'Aquila RT; Hirsch MS
J Infect Dis; 1991 Oct; 164(4):646-55. PubMed ID: 1716649
[TBL] [Abstract][Full Text] [Related]
38. Biological comparison of wild-type and zidovudine-resistant isolates of human immunodeficiency virus type 1 from the same subjects: susceptibility and resistance to other drugs.
Rooke R; Parniak MA; Tremblay M; Soudeyns H; Li XG; Gao Q; Yao XJ; Wainberg MA
Antimicrob Agents Chemother; 1991 May; 35(5):988-91. PubMed ID: 1649576
[TBL] [Abstract][Full Text] [Related]
39. Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1.
Hu Z; Giguel F; Hatano H; Reid P; Lu J; Kuritzkes DR
J Virol; 2006 Jul; 80(14):7020-7. PubMed ID: 16809307
[TBL] [Abstract][Full Text] [Related]
40. A novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (-)-beta-2',3'-dideoxy-3'-thiacytidine and 3'-azido-3'-deoxythymidine.
Smith RA; Remington KM; Preston BD; Schinazi RF; North TW
J Virol; 1998 Mar; 72(3):2335-40. PubMed ID: 9499094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
